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Abstract: Circulating fatty acids (FAs) increase with obesity and can drive mitochondrial damage
and inflammation. Nicotinamide nucleotide transhydrogenase (NNT) is a mitochondrial protein
that positively regulates nicotinamide adenine dinucleotide phosphate (NADPH), a key mediator
of energy transduction and redox homeostasis. The role that NNT-regulated bioenergetics play in
the inflammatory response of immune cells in obesity is untested. Our objective was to determine
how free fatty acids (FFAs) regulate inflammation through impacts on mitochondria and redox
homeostasis of peripheral blood mononuclear cells (PBMCs). PBMCs from lean subjects were
activated with a T cell-specific stimulus in the presence or absence of generally pro-inflammatory
palmitate and/or non-inflammatory oleate. Palmitate decreased immune cell expression of NNT,
NADPH, and anti-oxidant glutathione, but increased reactive oxygen and proinflammatory Th17
cytokines. Oleate had no effect on these outcomes. Genetic inhibition of NNT recapitulated the
effects of palmitate. PBMCs from obese (BMI >30) compared to lean subjects had lower NNT and
glutathione expression, and higher Th17 cytokine expression, none of which were changed by
exogenous palmitate. Our data identify NNT as a palmitate-regulated rheostat of redox balance that
regulates immune cell function in obesity and suggest that dietary or therapeutic strategies aimed at
increasing NNT expression may restore redox balance to ameliorate obesity-associated inflammation.
Keywords: mitochondria; nicotinamide nucleotide transhydrogenase; oleate; palmitate; peripheral
blood mononuclear cells, reactive oxygen species, Th17 cytokines

1. Introduction
Metabolic diseases like obesity are characterized by mitochondrial dysfunction, redox imbalance,
and chronic inflammation. However, the relationships amongst these physiological changes and how
they promote metabolic dysfunction in obesity [1,2] is not well understood. Mitochondria generate
cellular reactive oxygen species (ROS) mainly due to respiration-linked electron leakage that generates
superoxide anion and other redox changes. These changes are kept in check by anti-oxidants under
homeostatic conditions that are required for normal immune function [3]. Excess ROS, generated
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by over-exuberant mitochondria amidst deficiencies in anti-oxidants such as nicotinamide adenine
dinucleotide phosphate (NADPH) and reduced glutathione (GSH), can trigger aberrant cellular
signaling and other measures of damage that may upregulate pro-inflammatory cytokine expression [4]
to pathogenic levels. Such mechanisms may support the unresolved inflammation that associates with
obesity complications like type 2 diabetes (T2D) [5].
Nicotinamide nucleotide transhydrogenase (NNT) is an inner mitochondrial membrane protein
that catalyzes the reduction of NADP+ by NADH and the conversion of NADH to NAD+ [6–9]. NNT
has been implicated in redox balance and inflammation. Knockdown of NNT in human adrenocortical
cells resulted in impaired redox potential, increased mitochondrial ROS and apoptosis [10]. Liver
mitochondria from C57BL/6J mice, which lack NNT due to a spontaneous mutation, have major redox
alterations including higher H2 O2 , spontaneous NADPH oxidation and lower GSH compared to a
BL/6J sub-strain with a functional NNT gene [11]. Similarly, macrophages from C57BL/6J mice with
an NNT transgene have lower ROS and less cytokine production than non-transgenic counterparts [12].
Whether ROS from specific organelle sources and/or antioxidant regulation by NNT simply parallels
or directly causes pro-inflammatory cytokine production was not addressed by these studies. However,
these data raise the possibility that obesity-associated mitochondrial dysfunction interpreted in the
context of dyslipidemia perturb NNT, redox balance, and downstream outcomes like inflammation.
The objective of our study was to assess causal links amongst obesity-associated lipid shifts,
NNT/ROS expression, and inflammation in peripheral blood mononuclear cells (PBMCs) from
lean subjects to determine whether this pathway triggers the chronic inflammation that promotes
obesity-associated metabolic decline. We used a combination of saturated and monounsaturated fatty
acids, T cell-targeted stimuli, and genetic inhibition of NNT to show that palmitate decreases NNT
and GSH to promote redox imbalance and thereby the Th17 cytokines that characterize inflammation
in T2D [5]. PBMCs from obese subjects had lower expression of NNT and GSH compared to lean
age-matched subjects that did not further change in response to palmitate ex vivo, consistent with
the interpretation that this in vitro-induced pathway is active in people. Collectively these data
indicate that dietary or therapeutic strategies aimed at increasing NNT expression may be beneficial
for modulating mitochondrial redox balance to ameliorate obesity-associated inflammation.
2. Materials and Methods
2.1. Human Subjects Sample Collection
In accordance with the Declaration of Helsinki, informed consent for all human samples was
obtained following Institutional Review Board-approved protocols at Boston University, University of
Kentucky, and The Forsyth Institute (Ethical code numbers H27007, 44131, and 00000037, respectively).
Peripheral blood was obtained from normoglycemic subjects who were lean (avg: 33 years; BMI
22.71 kg/m2 ) or obese (avg: 39.6 years; BMI 34.15 kg/m2 ), with additional characteristics shown in
Table 1. Exclusion criteria were smoking, recent use of antibiotics or anti-inflammatory medications
i.e., NSAIDs/steroids, recent (within two weeks) colds or flu, diabetes or diabetes medications, and
any history of cancer, hyperglycemia, and auto-immune diseases.
Table 1. Description of research subjects.

Total N
Age, years [mean (range)]
A1c, % [mean (range)]
BMI, kg m−2 [mean (range)] *
Females [N (%)]
Males [N (%)]

Lean

Obese

12
33 (28–45)
5.1 (4.5–5.6)
22.71 (21.1–24.4.)
7 (58.33%)
5 (41.66%)

8
39.6 (30–47)
5.3 (5–5.5)
33.94 (30.4–40.8)
4 (50%)
4 (50%)

* p < 0.05 compared to lean.
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2.2. Isolation of PBMCs and T Cells
Fifty milliliters of peripheral blood were collected into acid/citrate/dextrose containing tubes by
venous puncture. PBMCs were purified by histopaque 1077 then frozen at −80 ◦ C under controlled
cooling conditions in a Mr. Frosty apparatus (Nalgene, Sigma Aldrich, St Louis, MO, USA). For
multi-week storage, cells were moved to −170 ◦ C following 1–7 days at −80 ◦ C. PBMCs from the
subjects were stimulated in vitro for 40 h with T cell-targeted αCD3/αCD28 Dynabeads (Thermo Fisher
Scientific, 11132D, Waltham, MA, USA) at 2 µL Dynabeads per 100k cells. In some cultures, cells were
co-treated with 400 µM palmitate (pal) (C16:0) coupled to fatty acid-free Bovine Serum Albumin (BSA)
at a ratio of 2 mol palmitate to 1 mole BSA, or 400 µM oleate, or a combination of palmitate and oleate.
These fatty acid concentrations mimic concentrations achievable in serum [13]. Control cells were
treated with 1% BSA. The mitochondrial ROS scavenger MitoTempo (mito)(10 µM) or a general ROS
scavenger N-acetyl cysteine (NAC) was added for the last 20 h of incubation (20 h post-stimulation)
for some cultures. All treatments were done in RPMI media with 5 mM glucose (normoglycemic).
Supernatants were collected and stored at −80 ◦ C. Cells were assayed as outlined below.
2.3. Immunoblotting
Immunoblotting was used to quantify protein expression as we published [14,15]. The procedure
was modified according to the cell type from which the proteins were extracted. Thirty µL of 1X cell
lysis buffer (Cell Signaling Technology, Danvers, MA, USA) was added to 1 × 106 cells and incubated
on ice for 20 min. Cells were then centrifuged at 13,000 rpm for 20 min and supernatant was collected.
A Bicinchoninic Assay (Thermo Fisher Scientific, Waltham, MA, USA) assessed protein concentration.
Twenty µg protein was loaded in polyacrylamide gels and electrophoresis was performed at 100 V for
1 h. Transfer of protein to polyvinylidene difluoride (PVDF) membrane was performed at 45 V for 5 h.
The membrane was blocked for 30 min at room temperature (RT) in blocking buffer containing 2%
bovine serum albumin in TBST followed by overnight incubation at 4 ◦ C in the respective primary
antibodies. The membrane was washed 3X with 1X TBST and incubated with secondary antibodies
for 2 h at RT, then imaged. Table 2 lists the antibodies used in this study. All antibodies were
used at a dilution of 1:500 except β-actin which was used at 1:10,000. We quantified NNT, isocitrate
dehydrogenase 2 (IDH2), malic enzyme 2 (ME2), glutamate cysteine ligase catalytic subunit (GCLC),
heat shock protein 60 (Hsp60) and mitochondrial aconitase (m-aconitase) expression on western blots
using Image studio lite (Licor, Lincoln, NE, USA) [16].
Table 2. Antibodies used in this study.
Protein

Catalog #

Company

NNT
m-aconitase
Hsp60
GCLC
IDH2
B-Actin
Malic enzyme

ab110352
ARP40390_P050
12165S
ARP54577_P050
ab131263
3700
12399S

Abcam
Aviva biologicals
Cell signaling technology
Aviva biologicals
Abcam
Cell signaling technology
Cell signaling technology

All antibodies were used at a dilution of 1:500 except β-actin (1:10,000).

2.4. ROS Quantification
ROS was quantified using 20 ,70 –dichlorofluorescin diacetate (DCFDA) fluorescence
(Sigma-Aldrich, D6883, St Louis, MO, USA) normalized to cell number [14,17]. Twenty-five mM
glucose (Sigma Aldrich, D8270) and 50 µM tert-butyl hydrogen peroxide (TBHP) (Sigma Aldrich,
416665) were used as positive controls. The free radical scavenger Tempol (50 µM; Sigma Aldrich
SML0737) was used to manipulate ROS generation and served as a control [14].
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2.5. Mitochondrial Measures
Mitochondrial mass was quantified in PBMCs after stimulation +/− fatty acids using Mitotracker
green fluorescence. PBMCs were incubated with αCD3/αCD28 ± 400 µM palmitate and/or oleate for
40 h then were washed twice with 1X PBS and incubated with 40 nM Mitotracker green (9074S, Cell
Signaling Technology, Danvers, MA, USA) in 5 mM glucose-containing RPMI for 30 min. Mitotracker
green fluorescence was assessed via fluorescence spectrophotometry (Biotek, Winooski, VT, USA) and
the results were normalized to cell numbers.
2.6. Mitochondrial Membrane Potential
αCD3/αCD28-stimulated PBMCS ± palmitate and/or oleate were incubated with 400 nM
tetramethylrhodamine, ethyl ester (TMRE), a cell-permeable positively-charged dye that accumulates
in mitochondria with high membrane potential, for 30 min. The cells were assayed using microplate
spectrophotometry (Biotek). Fifty µM FCCP was the positive control.
2.7. Measurement of Cellular Antioxidants
Cellular GSH was measured using a colorimetric assay (BioVision, Milpitas, CA, USA) according
to manufacturer’s protocol. Cellular NADPH was quantitated with a colorimetric assay according to
manufacturer’s instructions (BioVision).
2.8. Measurement of Plasma Free Fatty Acid
Plasma free fatty acids were quantitated using EnzyChrome free fatty acid assay kit (BioAssay
Systems, EFFA 100, Hayward, CA, USA) according to manufacturer’s instructions.
2.9. Cytokine Analysis
The Milliplex Th17 cytokine multiplex kit (Millipore, Burlington, MA, USA) was used to
assess protein accumulation in all supernatants in technical duplicate on a Luminex FlexMAP 3D
instrument (Luminex, Austin, TX, USA). Alternatively, we quantified IL-17A/F and IL-23 using
the Legend Max human ELISA kit (Biolegend, San Diego, CA, USA), performed according to
manufacturer’s instructions. The IL-17A/F ELISA does not distinguish between the two isotypes,
which heterodimerize to mediate a large portion of “IL-17” activity [18].
2.10. Small Interference RNA
Small interference RNA (siRNA)-mediated knockdown of NNT was performed using Accell
siRNA (Dharmacon, Lafayette, CO, USA) following manufacturer’s guidelines. Scrambled sequences
were used as controls. The siRNA (1 µM) was diluted in Accell siRNA delivery medium and added to
PBMCs with 2% FBS and 300 IU of IL-2. Cells were incubated ~40 h prior to assessing knockdown
efficiency via immunoblotting and subsequent analysis.
2.11. Statistical Analyses
Data are presented as mean ± standard error of the mean (SEM). For comparison among three or
more groups a one-way ANOVA and a Tukey’s post hoc test was used to identify differences. Unpaired
2-tailed t-tests compared means of two values. Significance was accepted when p < 0.05.
3. Results
3.1. Palmitate Decreased PBMC Membrane Potential
Fatty acid oxidation by T cell mitochondria regulates T cell function [19], but the impact of free
fatty acids (FFAs) on mitochondrial membrane potential and mass, as preliminary indicators of T cell
function, is untested. We activated PBMCs from lean subjects with T cell-specific αCD3/αCD28 in the
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presence of 400 µM palmitate or oleate alone or in combination, then quantified membrane potential
and mitochondrial content. Palmitate alone or in combination with oleate decreased membrane
potential, but oleate alone had no effect, as measured by TMRE fluorescence (Figure 1A).
potential, but oleate alone had no effect, as measured by TMRE fluorescence (Figure 1A). Mitochondrial
Mitochondrial content was similar amongst treatments, as measured by Mitotracker green
content was similar amongst treatments, as measured by Mitotracker green fluorescence and expression
fluorescence and expression of the inner mitochondrial proteins Hsp60 and m-aconitase on Western
of the inner mitochondrial proteins Hsp60 and m-aconitase on Western blots (Figure 1B–D). We
blots (Figure 1B–D). We conclude that palmitate dissipates PBMC mitochondrial membrane potential
conclude that palmitate dissipates PBMC mitochondrial membrane potential without changing
without changing mitochondrial mass, and that oleate cannot restore baseline membrane potential in
mitochondrial mass, and that oleate cannot restore baseline membrane potential in the presence
the presence of palmitate.
of palmitate.

Figure 1. Palmitate decreased peripheral blood mononuclear cells (PBMC) membrane potential without
Figure 1. Palmitate decreased peripheral blood mononuclear cells (PBMC) membrane potential
altering mitochondrial mass: PBMCs isolated from normoglycemic, lean subjects (ave: 33 years; BMI
without altering mitochondrial mass: PBMCs isolated from normoglycemic, lean subjects (ave: 33
22.71 kg/m2 ) were treated with 400 µM palmitate (pal) or oleate (ole) or a mixture of palmitate and
years; BMI 22.71 kg/m2) were treated with 400 μM palmitate (pal) or oleate (ole) or a mixture of
oleate (pal + ole) prior to measuring (A) Mitochondrial membrane potential with tetramethylrhodamine
palmitate and oleate (pal+ole) prior to measuring (A) Mitochondrial membrane potential with
ethyl ester (TMRE); (B) Mitochondrial mass with mitotracker green fluorescence, or mitochondrial
tetramethylrhodamine ethyl ester (TMRE); (B) Mitochondrial mass with mitotracker green
inner membrane proteins (C) Hsp60 and (D) m-aconitase. N = 5 each treatment. Each N represents
fluorescence, or mitochondrial inner membrane proteins (C) Hsp60 and (D) m-aconitase. N = 5 each
cells from one subject. * p < 0.05 vs. control (con).
treatment. Each N represents cells from one subject. * p < 0.05 vs control (con).

3.2. Palmitate Altered the Cellular Redox Balance
3.2. Palmitate Altered the Cellular Redox Balance
The observation that palmitate lowered membrane potential in PBMCs suggested that palmitate
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3.4. Palmitate Increased Proinflammatory Cytokine Production by PBMCs
3.4. Palmitate Increased Proinflammatory Cytokine Production by PBMCs
T cell cytokines promote insulin resistance in animal models of obesity [20,21], while Th1 and
T
cell cytokines promote insulin resistance in animal models of obesity [20,21], while Th1 and
Th17 cytokines mathematically predict glycemic control and type 2 diabetes, respectively, in people [5].
Th17
cytokines mathematically predict glycemic control and type 2 diabetes, respectively, in people
To identify links between palmitate-induced redox/mitochondrial changes and obesity-associated
[5]. To identify links between palmitate-induced redox/mitochondrial changes and obesityinflammation, we stimulated PBMCs with αCD3/αCD28 in the presence of palmitate and quantified
associated inflammation, we stimulated PBMCs with αCD3/αCD28 in the presence of palmitate and
cytokines. Palmitate increased production of multiple (but not all) Th17-associated cytokines (IL-17A,
quantified cytokines. Palmitate increased production of multiple (but not all) Th17-associated
-17F, and -23, but not IL-21) with insignificant/variable effects on Th1 (IL-6, IL-12, IFNγ) and Th2
cytokines (IL-17A, -17F, and -23, but not IL-21) with insignificant/variable effects on Th1 (IL-6, IL-12,
(IL-4) cytokines (Figure 4). Oleate treatment had no effect on classically defined Th17 cytokines, but
IFNγ) and Th2 (IL-4) cytokines (Figure 4). Oleate treatment had no effect on classically defined Th17
increased GMCSF and IL-9 (Figure 4 D,E), which have multiple cellular origins [22–24] and pleotropic
cytokines, but increased GMCSF and IL-9 (Figure 4 D,E), which have multiple cellular origins [22–
effects on inflammation. Unstimulated PBMCs produced low/unmeasurable amounts of all cytokines
24] and pleotropic effects on inflammation. Unstimulated PBMCs produced low/unmeasurable
measured (data not shown). We conclude that palmitate-associated changes in mitochondrial function
amounts of all cytokines measured (data not shown). We conclude that palmitate-associated changes
and redox balance parallel Th17 cytokine activation in immune cells from lean subjects.
in mitochondrial function and redox balance parallel Th17 cytokine activation in immune cells from
lean subjects.
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Figure 4. Palmitate promotes production of characteristic Th17 cytokines. Cytokine production from
Figure 4. Palmitate promotes production of characteristic Th17 cytokines. Cytokine production from
cells stimulated in the presence or absence of palmitate (pal) and oleate (ole) per Figure 1 and assessed
cells stimulated in the presence or absence of palmitate (pal) and oleate (ole) per Figure 1 and assessed
via multiplex. The concentrations of other cytokines assessed by the multiplex assay (IL-10, IL-13, ILvia
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To establish cause/effect relationships between palmitate-mediated decrease in NNT expression
and theToTh17
inflammation
that characterizes
type 2 diabetes
[5], wein
treated
establish
cause/effect
relationshipsobesity-associated
between palmitate-mediated
decrease
NNT expression
PBMCs
from
lean
subjects
with
NNT-specific
siRNA
and
analyzed
redox
and
cytokine
outcomes.
We we treated
and the Th17 inflammation that characterizes obesity-associated type 2 diabetes [5],
confirmed
NNT
siRNA
decreased
NNT
protein
~75%
relative
to
a
scrambled
siRNA
control
(Figure
PBMCs from lean subjects with NNT-specific siRNA and analyzed redox and cytokine outcomes.
5A). Analysis of ROS and NADPH in the NNT knock-down showed the predicted changes (Figure
We confirmed NNT siRNA decreased NNT protein ~75% relative to a scrambled siRNA control
5B,C). Both IL-17A/F and IL-23 expression were significantly higher in NNT knockdown cells
(Figure 5A). Analysis of ROS and NADPH in the NNT knock-down showed the predicted changes
compared to control cells (Figure 5D,E). We conclude that experimental NNT knockdown
(Figure 5B,C).
Both IL-17A/F and
IL-23
expression
higher in NNT knockdown cells
recapitulates
palmitate-downstream
redox
imbalance
andwere
Th17 significantly
cytokine up-regulation.
compared
to control
cells32–40
(Figure
5D,E).
We conclude
thatraising
experimental
NNT that
knockdown
Th17 cytokines
require
h for
detectable
expression,
the possibility
ROS fromrecapitulates
palmitate-downstream
imbalance and
Th17
cytokine
up-regulation.
either
mitochondrial and/orredox
non-mitochondrial
sources
may
be required
at multiple points along this
relatively
long
timelinerequire
for NNT-mediated
inflammation.
To test the
importance
of ROSthat
in ROS from
Th17
cytokines
32–40 h for detectable
expression,
raising
the possibility
maintenance
of
the
events
that
culminate
in
Th17
cytokine
production
many
hours
later,
we
added
either mitochondrial and/or non-mitochondrial sources may be required at multiple points along this
MitoTempo(mito)
or a general
ROS scavenger N-acetyl
cysteine To
(NAC)
at 20importance
h post-stimulation,
relatively long timeline
for NNT-mediated
inflammation.
test the
of ROS and
in maintenance
quantified cytokines by ELISA at 40 h. MitoTempo failed to impact IL-17A/F production under
of the events that culminate in Th17 cytokine production many hours later, we added MitoTempo(mito)
palmitate +/ oleate co-treatment (Figure 5F), supporting the interpretation that palmitate/NNTor a general ROS scavenger N-acetyl cysteine (NAC) at 20 h post-stimulation, and quantified cytokines
triggered mitochondrial ROS is not required for maintenance of cytokine production. Although NAC
by ELISA at 40 h. MitoTempo failed to impact IL-17A/F production under palmitate +/ oleate
significantly blunted IL-17A/F production, interpretation is confounded by the ability of NAC to
co-treatment
(Figureand
5F),thus
supporting
the interpretation
that
palmitate/NNT-triggered
mitochondrial
activate
the proteasome
affect multiple
NF-κB regulated
inflammatory
genes [25]. Addition
ROS
is
not
required
for
maintenance
of
cytokine
production.
Although
NAC
significantly
blunted
of MitoTempo at time zero significantly compromised cell viability, making interpretations of the
IL-17A/F
is confounded by pathway
the ability
of NACWe
to conclude
activate the
role
of early production,
mitochondrialinterpretation
ROS on the palmitate-NNT-Th17
uncertain.
thatproteasome
anand
initial
burst
of mitochondrial
ROSregulated
in the first 20
h post-stimulation,
in combination
with
thus
affect
multiple NF-κB
inflammatory
genesperhaps
[25]. Addition
of MitoTempo
at time
the
ROS-induced
ROS
generation likely
induced atmaking
later time
points, is sufficient
to support
Th17
zero
significantly
compromised
cell viability,
interpretations
of the role
of early
mitochondrial
cytokine
in response to palmitate.
ROS onproduction
the palmitate-NNT-Th17
pathway uncertain. We conclude that an initial burst of mitochondrial

ROS in the first 20 h post-stimulation, perhaps in combination with the ROS-induced ROS generation
likely induced at later time points, is sufficient to support Th17 cytokine production in response
to palmitate.
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Both
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NNT and GSH expression were lower in αCD3/αCD28-stimulated PBMCs from obese compared to
GSH expression were lower in αCD3/αCD28-stimulated PBMCs from obese compared to lean subjects
lean subjects (Figure 6B,C), and ROS was higher at both time points tested (Figure 6D), as was IL(Figure 6B,C), and ROS was higher at both time points tested (Figure 6D), as was IL-17A/F (Figure 6E).
17A/F (Figure 6E). Exogenous palmitate did not change any measures of redox imbalance or
Exogenous palmitate did not change any measures of redox imbalance or inflammation in cells from
inflammation in cells from obese subjects (Figure 6 F-H), suggesting redundant regulatory pathways.
obese subjects (Figure 6F–H), suggesting redundant regulatory pathways. MitoTempo had no impact
MitoTempo had no impact on IL-17A/F, GSH or NNT in cells from obese subjects, indicating that
on IL-17A/F, GSH or NNT in cells from obese subjects, indicating that non-mitochondrial sources of
non-mitochondrial sources of ROS added a layer of regulation absent in palmitate-treated cells from
addedThese
a layer
of regulation
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from lean
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Figure 7. Schematic description of the findings. The saturated fatty acid palmitate blunts the expression
Figure 7. Schematic description of the findings. The saturated fatty acid palmitate blunts the
of the mitochondrial redox regulator NNT. This leads to decreased cellular NADPH and glutathione
expression of the mitochondrial redox regulator NNT. This leads to decreased cellular NADPH and
anti-oxidant, resulting in a redox imbalance, more mitochondrial ROS, and higher concentrations of
glutathione anti-oxidant, resulting in a redox imbalance, more mitochondrial ROS, and higher
proinflammatory Th17 cytokines. These events become mitochondrial ROS-independent following
concentrations of proinflammatory Th17 cytokines. These events become mitochondrial ROS20 h of stimulation, and partially recapitulate the T2D-associated Th17 cytokine profile. Knock-down
independent following 20 h of stimulation, and partially recapitulate the T2D-associated Th17
of NNT by siRNA recapitulates the effects of palmitate.
cytokine profile. Knock-down of NNT by siRNA recapitulates the effects of palmitate.

NNT has also been identified as a regulator of metabolic health in multiple studies. Quantitative
Author Contributions: G.M., A.K, L.P.B., and M.A. investigated the project. B.N. and L.P.B. conceptualized and
trait locus mapping highlighted NNT as important for glycemic control and insulin secretion in
wrote the manuscript. P.A..K. reviewed and edited the manuscript. P. A..K. and H.H. recruited subjects for the
C57BL/6
mice, although the investigators assumed NNT function was mainly in the pancreatic beta
study.
cells [32,33]. Comparison of C57BL/6 mice +/- functional NNT showed NNT protected against glucose
Funding: This work was supported by The College of Health Sciences, Merrimack College (LPB), R01DK108056
intolerance upon high fat diet feeding, though the underlying cause of greater weight gain (which
(BSN), and UL1TR001998 (PAK).
generally challenges euglycemia) in the absence of NNT was not investigated [34]. NNT mRNA
Acknowledgments:
We thank
Dequina and
Nicholas-Alvarado,
of Reproductive
Medicine,
University
expression
was assessed
in visceral
subcutaneousDepartment
adipose tissues
of 221 human
subjects
of wide
of California, San Diego, CA, USA and Madhumita Jagannathan-Bogdan, Lycera Corp, Ann Arbor, MI, USA for
range of BMI, insulin sensitivity and glucose tolerance. The study concluded that, in contrast to findings
their scientific input.
herein and to published work in mice, NNT mRNA expression was higher in the visceral fat of obese
subjects and positively correlated with BMI, body weight, percent body fat, waist to hip circumference
and fasting plasma insulin [35]. The authors raise the possibility that higher NNT resulted in feed
forward loops that culminate in beta cell “burn out” amongst other explanations for this unexpected
finding. Another study reported that NNT and GSH mRNA, among other indicators of mitochondrial
function, increase in subcutaneous and visceral adipose tissue 12 months after sleeve gastrectomy along
with a decrease in adipokine mRNAs (a measure of inflammation) [36]. It is important to note that the
impact of bariatric surgery on inflammation is variable across studies [37] The results from these studies
disagree indicating that further work is needed to determine whether technical differences (mRNA vs.
protein quantification), cell type differences (total visceral adipose tissue vs. circulating immune cells),
or species differences (mouse vs. human) explain the apparent discrepancies amongst these findings.
Newly appreciated links from FFA excess to NNT/redox imbalance terminating in obesity-associated
Th17 inflammation may more broadly represent a regulatory pathway that drives functions of other cell
types in obesity through similar mitochondrial machinery. NNT-targeted interventions may therefore
normalize multiple cellular functions that perpetuate obesity-associated complications.
The T2D-associated Th17 profile was derived from a comparison of obese subjects with and
without T2D [5]. It is difficult to say whether partial recapitulation of this profile (IL-17A, -17F, -23) by
palmitate treatment of cells from lean subjects herein is more modeling the obese/normoglycemic status
tested here, or the obese/T2D status that was tested by our profiling work. Partial recapitulation of the
profile by palmitate could mimic the physiology somewhere along the continuum of progression from
obesity to obesity-associated T2D, a speculation that would require substantial additional investigation.
Author Contributions: G.M., A.K., L.P.B., and M.A. investigated the project. B.N. and L.P.B. conceptualized
and wrote the manuscript. P.A.K. reviewed and edited the manuscript. P.A.K. and H.H. recruited subjects for
the study.
Funding: This work was supported by The College of Health Sciences, Merrimack College (LPB), R01DK108056
(BSN), and UL1TR001998 (PAK).

Biomolecules 2019, 9, 79

12 of 14

Acknowledgments: We thank Dequina Nicholas-Alvarado, Department of Reproductive Medicine, University of
California, San Diego, CA, USA and Madhumita Jagannathan-Bogdan, Lycera Corp, Ann Arbor, MI, USA for their
scientific input.
Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design of the
study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to
publish the results.

References
1.

2.
3.
4.

5.

6.
7.

8.
9.

10.

11.

12.

13.

14.

15.

Salzano, S.; Checconi, P.; Hanschmann, E.M.; Lillig, C.H.; Dowler, L.D.; Chan, P.; Vaudry, D.; Mengozzi, M.;
Coopo, L.; Sacre, S.; et al. Linkage of inflammation and oxidative stress via release of glutathionylated
peroxiredoxin-2, which acts as a danger signal. Proc. Natl. Acad. Sci. USA 2014, 111, 12157–12162. [CrossRef]
[PubMed]
Griffiths, H.R.; Gao, D.; Pararasa, C. Redox regulation in metabolic programming and inflammation. Redox.
Biol 2017, 12, 50–57. [CrossRef] [PubMed]
Kienhofer, D.; Boeltz, S.; Hoffmann, M.H. Reactive oxygen homeostasis—The balance for preventing
autoimmunity. Lupus 2016, 25, 943–954. [CrossRef] [PubMed]
Haddad, J.J. Glutathione depletion is associated with augmenting a proinflammatory signal: Evidence for an
antioxidant/pro-oxidant mechanism regulating cytokines in the alveolar epithelium. Cytokines Cell Mol. Ther.
2000, 6, 177–187. [CrossRef] [PubMed]
Ip, B.; Cilfone, N.; Belkina, A.C.; DeFuria, A.C.; Jagannathan-Bogdan, M.; Zhu, M.; Kuchibhatla, R.;
McDonnell, M.E.; Xiao, Q.; Kepler, T.B.; et al. Th17 cytokines differentiate obesity from obesity-associated
type 2 diabetes and promote TNFalpha production. Obesity (Silver. Spring) 2016, 24, 102–112. [CrossRef]
[PubMed]
Rydstrom, J.; Hoek, J.B.; Ernster, L. On the oxidation of reduced nicotinamide dinucleotide phosphate by
submitochondrial particles from beef heart. Biochim. Biophys. Acta 1973, 305, 694–698. [CrossRef]
Busanello, E.N.B.; Figureueira, T.R.; Marques, A.C.; Navarro, C.D.C. Facilitation of Ca(2+) -induced opening
of the mitochondrial permeability transition pore either by nicotinamide nucleotide transhydrogenase
deficiency or statins treatment. Cell. Biol. Int. 2018, 42, 742–746. [CrossRef] [PubMed]
Xiao, W.; Wang, R.S.; Handy, D.E.; Loscalzo, J. NAD(H) and NADP(H) Redox Couples and Cellular Energy
Metabolism. Antioxid. Redox. Signal. 2018, 28, 251–272. [CrossRef] [PubMed]
Ho, H.Y.; Lin, Y.T.; Lin, G.; Wu, P.R.; Cheng, M.L. Nicotinamide nucleotide transhydrogenase (NNT)
deficiency dysregulates mitochondrial retrograde signaling and impedes proliferation. Redox. Biol. 2017, 12,
916–928. [CrossRef] [PubMed]
Meimaridou, E.; Kowalczyk, J.; Guasti, L.; Hugues, C.R.; Wagner, F.; Frommolt, P.; Nürnberg, P.; Mann, N.P.;
Banerjee, R.; Saka, H.N.; et al. Mutations in NNT encoding nicotinamide nucleotide transhydrogenase cause
familial glucocorticoid deficiency. Nat. Genet. 2012, 44, 740–742. [CrossRef] [PubMed]
Ronchi, J.A.; Figureueira, T.R.; Ravagnani, F.G.; Oliveira, H.C.; Vercesi, A.E.; Castilho, R.F. A spontaneous
mutation in the nicotinamide nucleotide transhydrogenase gene of C57BL/6J mice results in mitochondrial
redox abnormalities. Free Radic. Biol Med. 2013, 63, 446–456. [CrossRef] [PubMed]
Ripoll, V.M.; Meadows, N.A.; Bangert, M.; Lee, A.W.; Kadioglu, A.; Cox, R.D. Nicotinamide nucleotide
transhydrogenase (NNT) acts as a novel modulator of macrophage inflammatory responses. FASEB J. 2012,
26, 3550–3562. [CrossRef] [PubMed]
Abdelmagid, S.A.; Clarke, S.E.; Nielsen, D.E.; Badawi, A.; El-Sohemy, A.; Mutch, D.M.; Ma, D.W.
Comprehensive profiling of plasma fatty acid concentrations in young healthy Canadian adults. PLoS ONE
2015, 10, e0116195. [CrossRef] [PubMed]
Bharath, L.P.; Ruan, T.; Li, Y.; Ravindran, A.; Wan, X.; Nhan, J.K.; Walker, M.L.; Deeter, L.; Goodrich, R.;
Johnson, E.; et al. Ceramide-Initiated Protein Phosphatase 2A Activation Contributes to Arterial Dysfunction
In Vivo. Diabetes 2015, 64, 3914–3926. [CrossRef] [PubMed]
Bharath, L.P.; Cho, J.M.; Park, S.K.; Ruan, T.; Li, Y.; Mueller, R.; Bean, T.; Reese, V.; Richardson, R.S.;
Cai, J.; et al. Endothelial Cell Autophagy Maintains Shear Stress-Induced Nitric Oxide Generation via
Glycolysis-Dependent Purinergic Signaling to Endothelial Nitric Oxide Synthase. Arterioscler. Thromb. Vasc.
Biol. 2017, 37, 1646–1656. [CrossRef] [PubMed]

Biomolecules 2019, 9, 79

16.
17.

18.
19.
20.

21.

22.

23.

24.
25.
26.
27.
28.
29.

30.

31.

32.

33.
34.

35.

36.

13 of 14

Kubli, D.A.; Gustafsson, A.B. Mitochondria and mitophagy: The yin and yang of cell death control. Circ. Res.
2012, 111, 1208–1221. [CrossRef] [PubMed]
Bharath, L.P.; Mueller, R.; Li, Y.; Ruan, T.; Kunz, D.; Goodrich, R.; Mills, T.; Deeter, L.; Sargsyan, A.; Anandh
Babu, P.V.; et al. Impairment of autophagy in endothelial cells prevents shear-stress induced increases in
nitric oxide bioavailability. Can. J. Physiol. Pharmacol. 2014, 92, 605–612. [CrossRef] [PubMed]
Goepfert, A.; Lehmann, S.; Wirth, E.; Rondeau, J.M. The human IL-17A/F heterodimer: A two-faced cytokine
with unique receptor recognition properties. Sci. Rep. 2017, 7, 8906. [CrossRef] [PubMed]
Weinberg, S.E.; Sena, L.A.; Chandel, N.S. Mitochondria in the regulation of innate and adaptive immunity.
Immunity 2015, 42, 406–417. [CrossRef] [PubMed]
Winer, S.; Chan, Y.; Paltser, G.; Truong, D.; Tsui, H.; Bahrami, J.; Dorfman, R.; Wang, Y.; Zielenski, J.;
Mastronardi, F.; et al. Normalization of obesity-associated insulin resistance through immunotherapy.
Nat. Med. 2009, 15, 921–929. [CrossRef] [PubMed]
Feuerer, M.; Herrero, L.; Cipolleta, D.; Naaz, A.; Wong, J.; Nayer, A.; Lee, J.; Goldfine, A.B.; Benoist, C.;
Shoelson, S.; et al. Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect
metabolic parameters. Nat. Med. 2009, 15, 930–939. [CrossRef] [PubMed]
Bhattacharya, P.; Budnick, I.; Singh, M.; Thiruppathi, M.; Altharshawi, K.; Elshabrawy, H.; Holterman, M.J.;
Prabhakar, B.S. Dual Role of GM-CSF as a Pro-Inflammatory and a Regulatory Cytokine: Implications for
Immune Therapy. J. Interferon Cytokine Res. 2015, 35, 585–599. [CrossRef] [PubMed]
Bhattacharya, P.; Thiruppathi, M.; Elshabrawy, H.A.; Alharshawi, K.; Kumar, P.; Prabhakar, B.S. GM-CSF:
An immune modulatory cytokine that can suppress autoimmunity. Cytokine 2015, 75, 261–271. [CrossRef]
[PubMed]
Goswami, R.; Kaplan, M.H. A brief history of IL-9. J. Immunol. 2011, 186, 3283–3288. [CrossRef] [PubMed]
Halasi, M.; Wang, M.; Chavan, T.S.; Gaponenko, V.; Hay, N.; Gartel, A.L. ROS inhibitor N-acetyl-L-cysteine
antagonizes the activity of proteasome inhibitors. Biochem. J. 2013, 454, 201–208. [CrossRef] [PubMed]
Boden, G. Obesity and free fatty acids. Endocrinol. Metab Clin. North. Am. 2008, 37, 635–646. [CrossRef]
[PubMed]
Jensen, M.D.; Haymond, M.W.; Rizza, R.A.; Cryer, P.E.; Miles, J.M. Influence of body fat distribution on free
fatty acid metabolism in obesity. J. Clin. Invest. 1989, 83, 1168–1173. [CrossRef] [PubMed]
Pongratz, R.L.; Kibbey, R.G.; Shulman, G.I.; Cline, G.W. Cytosolic and mitochondrial malic enzyme isoforms
differentially control insulin secretion. J. Biol Chem. 2007, 282, 200–207. [CrossRef] [PubMed]
Mandella, R.D.; Sauer, L.A. The mitochondrial malic enzymes. I. Submitochondrial localization and
purification and properties of the NAD(P)+-dependent enzyme from adrenal cortex. J. Biol Chem. 1975, 250,
5877–5884. [PubMed]
Yin, F.; Sancheti, H.; Cadenas, E. Silencing of nicotinamide nucleotide transhydrogenase impairs cellular
redox homeostasis and energy metabolism in PC12 cells. Biochim. Biophys. Acta 2012, 1817, 401–409.
[CrossRef] [PubMed]
Huang, T.T.; Naeemuddin, M.; Elchuri, S.; Yamaguchi, M.; Kozy, H.M.; Carlston, E.J.; Epstein, C.J. Genetic
modifiers of the phenotype of mice deficient in mitochondrial superoxide dismutase. Hum. Mol. Genet. 2006,
15, 1187–1194. [CrossRef] [PubMed]
Freeman, H.; Shimomura, K.; Cox, R.D.; Ashcroft, F.M. Nicotinamide nucleotide transhydrogenase: A link
between insulin secretion, glucose metabolism and oxidative stress. Biochem. Soc. Trans. 2006, 34, 806–810.
[CrossRef] [PubMed]
Freeman, H.; Shimomura, K.; Horner, E.; Cox, R.D.; Ashcroft, F.M. Nicotinamide nucleotide
transhydrogenase: A key role in insulin secretion. Cell. Metab. 2006, 3, 35–45. [CrossRef] [PubMed]
Nicholson, A.; Reifsnyder, P.C.; Malcolm, R.D.; Lucas, C.A.; MacGregor, G.R.; Zhang, W.; Leiter, E.H.
Diet-induced obesity in two C57BL/6 substrains with intact or mutant nicotinamide nucleotide
transhydrogenase (Nnt) gene. Obesity (Silver. Spring) 2010, 18, 1902–1905. [CrossRef] [PubMed]
Heiker, J.T.; Kern, M.; Kosacka, J.; Flehmig, G.; Stumvoll, M.; Shang, E.; Lohmann, T.; Dresler, M.; Kovacs, P.;
Blüher, M.; et al. Nicotinamide nucleotide transhydrogenase mRNA expression is related to human obesity.
Obesity (Silver. Spring) 2013, 21, 529–534. [CrossRef] [PubMed]
Mardinoglu, A.; Heiker, J.T.; Gärtner, D.; Björnson, E.; Schön, M.R.; Flehmig, G.; Klöting, N.; Krohn, K.;
Fasshauer, M.; Stumvoll, M.; et al. Extensive weight loss reveals distinct gene expression changes in human
subcutaneous and visceral adipose tissue. Sci. Rep. 2015, 5, 14841. [CrossRef] [PubMed]

Biomolecules 2019, 9, 79

37.

14 of 14

Hafida, S.; Mirshahi, T.; Nikolajczyk, B.S. The impact of bariatric surgery on inflammation: Quenching the
fire of obesity? Curr. Opin. Endocrinol. Diabetes Obes. 2016, 23, 373–378. [CrossRef] [PubMed]
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).

